Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
Total Valuation
Dr Reddy's Laboratories has a market cap or net worth of $13.00B. The enterprise value is $784.38B.
Market Cap$13.00B
Enterprise Value$784.38B
Share Statistics
Dr Reddy's Laboratories has 834,474,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding834,474,200
Owned by Insiders―
Owned by Institutions3.20%
Financial Efficiency
Dr Reddy's Laboratories’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 17.18%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)17.18%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee10.32M
Profits Per Employee2.06M
Employee Count27,048
Asset Turnover0.72
Inventory Turnover1.82
Valuation Ratios
The current PE Ratio of Dr Reddy's Laboratories is 18.45. Dr Reddy's Laboratories’s PEG ratio is 0.27.
PE Ratio18.45
PS Ratio0.00
PB Ratio3.32
Price to Fair Value3.66
Price to FCF21.94
Price to Operating Cash Flow16.22
PEG Ratio0.27
Income Statement
In the last 12 months, Dr Reddy's Laboratories had revenue of 279.16B and earned 55.68B in profits. Earnings per share was 66.80.
Revenue279.16B
Gross Profit163.61B
Operating Income67.73B
Pretax Income71.87B
Net Income55.68B
EBITDA88.42B
Earnings Per Share (EPS)66.80
Cash Flow
In the last 12 months, operating cash flow was 35.95B and capital expenditures -29.43B, giving a free cash flow of 6.52B billion.
Operating Cash Flow35.95B
Free Cash Flow6.52B
Free Cash Flow per Share7.81
Dividends & Yields
Dr Reddy's Laboratories pays an annual dividend of $0.096, resulting in a dividend yield of 0.63%
Dividend Per Share$0.096
Dividend Yield0.63%
Payout Ratio12.01%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change7.88%
50-Day Moving Average14.27
200-Day Moving Average14.51
Relative Strength Index (RSI)54.30
Average Volume (3m)1.69M
Important Dates
Dr Reddy's Laboratories upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.
Last Earnings DateMay 9, 2025
Next Earnings DateJul 24, 2025
Ex-Dividend DateJul 30, 2024
Financial Position
Dr Reddy's Laboratories as a current ratio of 2.58, with Debt / Equity ratio of 27.38%
Current Ratio2.58
Quick Ratio1.92
Debt to Market Cap0.02
Net Debt to EBITDA0.15
Interest Coverage Ratio39.58
Taxes
In the past 12 months, Dr Reddy's Laboratories has paid 16.19B in taxes.
Income Tax16.19B
Effective Tax Rate0.23
Enterprise Valuation
Dr Reddy's Laboratories EV to EBITDA ratio is 11.77, with an EV/FCF ratio of 57.80.
EV to Sales3.73
EV to EBITDA11.77
EV to Free Cash Flow57.80
EV to Operating Cash Flow22.90
Balance Sheet
Dr Reddy's Laboratories has $59.18B in cash and marketable securities with ₹51.09B in debt, giving a net cash position of -$8.09B billion.
Cash & Marketable Securities$59.18B
Total Debt₹51.09B
Net Cash-$8.09B
Net Cash Per Share-$9.70
Tangible Book Value Per Share$287.14
Margins
Gross margin is 54.23%, with operating margin of 24.26%, and net profit margin of 19.95%.
Gross Margin54.23%
Operating Margin24.26%
Pretax Margin25.74%
Net Profit Margin19.95%
EBITDA Margin31.67%
EBIT Margin26.36%
Analyst Forecast
The average price target for Dr Reddy's Laboratories is $16.90, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.90
Price Target Upside11.26% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast14.23%
EPS Growth Forecast-0.84%